Bayer unveils first look at its post-Xarelto, post-Eylea life—and it's better than expected

Investors have long been concerned about the future of Bayer’s pharma franchise, given the upcoming patent cliff facing its bread and butter—heart drug Xarelto and eye med Eylea.

Now the German conglomerate is providing a first look at life after those patent expirations, which are expected around 2023. And it looks better than analysts expected it would.